• Home
• Investors
• News and events
• Annual general meeting
• Letter to shareholders 2005

Letter to shareholders 2005

To the holders of the company's Ordinary Shares and American Depositary Shares and, for information, to the holders of the SmithKline Beecham plc Floating Rate Unsecured Loan Stock.

Dear Shareholder,

I am pleased to enclose the Notice of Meeting for the fifth Annual General Meeting ('AGM') of GlaxoSmithKline plc. The AGM will be held at 2.30pm on Wednesday, 25th May 2005 at the Queen Elizabeth II Conference Centre, Broad Sanctuary, Westminster, London SW1.

If you will not be attending you may wish to appoint a proxy electronically via www.shareview.co.uk or www.sharevote.co.uk or if you hold your shares in CREST via the CREST system or by completing and returning the enclosed form of proxy. In each case notice of your appointment of a proxy should reach the company's registrar no later than 2.30pm on Monday, 23rd May 2005.

The Annual Review enclosed contains summary financial statements for the year to 31st December 2004. A copy of the Annual Report is also enclosed for those who have requested a copy. A resolution referring to the financial statements is included in the ordinary business of the AGM. In addition, resolutions are proposed covering the election of two new Non-Executive Directors - Sir Deryck Maughan and myself. I also ask you to support the election of a new Executive Director, Mr Julian Heslop, our new Chief Financial Officer. Our Articles of Association require that every year a proportion of our current Directors must retire by rotation. I therefore ask you to support the re-election of Dr JP Garnier, Sir Ian Prosser, Dr Ronaldo Schmitz and Dr Lucy Shapiro who will each retire and offer themselves for re-election. Explanatory notes for all the business of the AGM are given on pages 4 and 5 of this document.

Your Board believes that the resolutions contained in the Notice of Meeting are in the best interests of the company and shareholders as a whole and recommends you to vote in favour of them, as your Directors intend to do in respect of their beneficial shareholdings.

Yours sincerely

Sir Christopher Gent

Chairman
GlaxoSmithKline